VYNE Therapeutics Inc. (VYNE)
- Previous Close
1.8800 - Open
1.9000 - Bid --
- Ask --
- Day's Range
1.8000 - 1.9000 - 52 Week Range
1.5700 - 4.4810 - Volume
28,572 - Avg. Volume
40,304 - Market Cap (intraday)
27.729M - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
1.07 - EPS (TTM)
1.7200 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
www.vynetherapeutics.comRecent News: VYNE
View MorePerformance Overview: VYNE
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VYNE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VYNE
View MoreValuation Measures
Market Cap
27.73M
Enterprise Value
-50.23M
Trailing P/E
1.07
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
113.32
Price/Book (mrq)
0.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.54%
Return on Equity (ttm)
-60.47%
Revenue (ttm)
486k
Net Income Avi to Common (ttm)
-28.01M
Diluted EPS (ttm)
1.7200
Balance Sheet and Cash Flow
Total Cash (mrq)
78.1M
Total Debt/Equity (mrq)
0.19%
Levered Free Cash Flow (ttm)
-13.92M